Rothschild & Co Redburn raises target for Abbott Laboratories stock to USD 127.00
Published on 10/02/2026 at 17:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Abbott Laboratories (ISIN US0028241000) saw Rothschild & Co Redburn upgrade its rating from neutral to buy and raise its price target from USD 119.00 to USD 127.00 in a note dated October 2, 2026, according to MarketBeat. The move puts fresh emphasis on whether Abbott can deliver its fiscal 2026 outlook before its next results.
Target rises as results approach
Rothschild & Co Redburn's new USD 127.00 target is USD 8.00 above its former USD 119.00 objective, while the rating changed from neutral to buy. The same MarketBeat report places the stock's 12-month consensus at Moderate Buy with an average target of USD 119.80.
Abbott's second-quarter 2026 revenue was USD 12.59 billion, up 13.00 percent year over year, while reported earnings per share reached USD 1.31 against USD 1.28 consensus. That comparison gives the upgrade a recent operating reference rather than relying only on valuation, as MarketBeat reported on October 1, 2026.
Guidance sets the next test
For fiscal 2026, Abbott's adjusted earnings per share guidance stands at USD 5.45-5.60. Analysts cited by Barchart expect adjusted earnings per share of USD 5.52 for the year and USD 1.43 in the third quarter, compared with USD 1.30 in the year-earlier quarter. The next scheduled reporting date is October 21, 2026, before the US market opens.
Abbott also declared a quarterly dividend of USD 0.63 per share on September 17, 2026, with an October 15, 2026 ex-dividend date and November 16, 2026 payment date, according to MarketBeat. The payout adds income support, but the upcoming results remain the clearest test of the guidance range.
Stock holds near its yearly midpoint
Abbott Laboratories stock was trading at EUR 85.92 at Lang & Schwarz on October 2, 2026 at 5:03 p.m. CEST, down minus 0.14 percent versus the prior close of EUR 86.04. The Lang & Schwarz price sits between the 52-week range of USD 81.97 to USD 135.37 reported for the NYSE listing, so the euro quote and the US dollar range are shown as separate market references.
The further course of trading is shown by the continuously updated real-time quote of Abbott Laboratories stock.
Abbott Laboratories stock at a glance
- Company: Abbott Laboratories
- ISIN: US0028241000
- Ticker: ABT
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 2, 2026, 5:03 p.m. CEST): EUR 85.92
- Change versus prior close: minus 0.14 percent
- Prior close Lang & Schwarz (October 1, 2026): EUR 86.04
- Market capitalization: USD 167.3 billion (as of October 2, 2026)
- 52-week range: USD 81.97-135.37 (as of October 2, 2026)
- Sector / Industry: Healthcare / Medical Devices
